Clinical trials: Psychosis; Acute
Schizophrenia
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
Olanzapine is one of the most effective and best tolerated of the atypical antipsychotics, but it is also particularly associated with weight gain and metabolic problems.
- Trial name
- GWMD09126 (NCT01491490)
- Testing
- GWP42003 : GWP42004 (40:1)
- Where
- 6 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- GW Research Ltd
Psychosis; Acute
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and…
- Trial name
- CINEMA (NCT07483294)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Northwell Health
Schizophrenia
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.
- Trial name
- NCT00580125
- Testing
- PF-00217830, Aripiprazole
- Where
- 26 sites in United States, India and 2 more
- Volunteers
- 164 people
- Sponsor
- Pfizer
Schizophrenia
Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic
The primary objective of the study is to evaluate the efficacy of quetiapine fumarate (Seroquel) with daily dose 600mg-750mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from…
- Trial name
- NCT00428350
- Testing
- Quetiapine Fumarate (Seroquel)
- Where
- 9 sites in China
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Schizophrenia
A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia
The purpose of this study is to compare the efficacy and side effects of 6 commonly used antipsychotic drugs in the treatment of schizophrenia in a Chinese population.
- Trial name
- NCT02192723
- Testing
- Typical antipsychotic, Risperidone, Olanzapine
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Beijing HuiLongGuan Hospital
Affective Psychosis, Bipolar, Manic Disorder
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks.
- Conditions
- Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania
- Trial name
- NCT00422123
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 51 sites in United States
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Schizophrenia
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia.
- Trial name
- NCT02477020
- Testing
- TAK-063 20 mg
- Where
- 15 sites in United States
- Volunteers
- 164 people
- Sponsor
- Takeda
Schizophrenia
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
Schizophrenia is a heterogeneous mental disorder that affects one percent of the world's population. Current antipsychotics are only partially effective, and their use is often associated with serious side effects.
- Trial name
- NCT02088060
- Testing
- Cannabidiol, Olanzapine
- Where
- 6 sites in Denmark, Germany
- Volunteers
- 150 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.
- Trial name
- ESPRIT (NCT00882518)
- Testing
- Quetiapine Fumarate (SEROQUEL) Extended-Release (XR), Chlorpromazine
- Where
- 11 sites in China
- Volunteers
- 388 people
- Sponsor
- AstraZeneca
Persistent Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Supported Employment and Education.
Psychotic disorders often develop a chronic course with devastating consequences for individuals, families, and societies usually with first onset during adolescence and early adulthood.
- Conditions
- Persistent Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified, Schizophrenia, Schizoaffective Disorder
- Trial name
- SEEearly (NCT05824117)
- Testing
- Individual Placement and Support (IPS)
- Where
- 6 sites in Germany
- Volunteers
- 184 people
- Sponsor
- Charite University, Berlin, Germany
Sleep Disturbance, Psychotic Disorders
Sleep Disturbances in Patients With Psychotic Symptoms (AkuSleep)
Sleep disturbance is recognized as a major problem for patients with psychosis and is seen in nearly all patients admitted in acute crisis to a psychiatric hospital.
- Trial name
- AkuSleep (NCT04290650)
- Testing
- Modified CBT for insomnia, Treatment as usual
- Where
- Norway
- Volunteers
- 75 people
- Sponsor
- Oslo University Hospital
Schizophrenia, Schizoaffective Disorder
Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
The purpose of this study is to prove safety and efficacy of aripiprazole.
- Trial name
- NCT00304655
- Testing
- Aripiprazole
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Acute Psychotic Symptoms
Quality Project to Evaluate and Validate the FAST-O Rating Scale
The purpose of this project is to test the reliability of the FAST-O Rating Scale in patients at acute wards or psychiatric intensive care units.
- Trial name
- FAST-O (NCT00913731)
- Where
- 5 sites in Sweden
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Schizophrenia
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
The purpose of this study is to explore tolerability, safety and effectiveness of flexibly dosed paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- PERFlexS (NCT00460512)
- Testing
- Paliperidone ER
- Where
- 231 sites in Belgium, Bulgaria and 20 more
- Volunteers
- 1,814 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia, Schizoaffective Disorder
Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
The aim of this study was to compare the efficacy and safety of intramuscular 10 mg olanzapine versus intramuscular 5 mg haloperidol plus lorazepam 2 mg in the treatment of acute agitated schizophrenic patients of Taiwanese…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Agitation
- Trial name
- NCT00797277
- Testing
- IM olanzapine, IM haloperidol plus lorazepam
- Where
- Taiwan
- Volunteers
- 67 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia, Schizoaffective Disorder
Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms
As of late Integrated Care Pathways (ICPs) have been shown to improve quality of care in the medical field with special attention given to mental health in particular.
- Trial name
- LLS-ICP (NCT02529163)
- Testing
- Late-life Schizophrenia ICP, Treatment as Usual
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Centre for Addiction and Mental Health
Depression, Sleep
The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression
The aim of this trial is to investigate the effects of a single bout of aerobic exercise on sleep in patients with depression.
- Conditions
- Depression, Sleep, Sleep Disorder, Sleep Disturbance
- Trial name
- EASED (NCT03673397)
- Testing
- Aerobic exercise, bicycle ergometer
- Where
- Switzerland
- Volunteers
- 92 people
- Sponsor
- Oberwaid AG
Schizophrenia
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period.
- Trial name
- NCT01175135
- Testing
- PF-02545920, Risperidone
- Where
- 46 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- Pfizer
Schizophrenia
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo.
- Trial name
- NCT00615433
- Testing
- Lurasidone, Olanzapine, Lurasidone 40 mg tablets
- Where
- 52 sites in United States, Colombia and 3 more
- Volunteers
- 478 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia
The study investigates the efficacy of aerobic exercise on cognitive performance and brain plasticity in schizophrenia.
- Trial name
- NCT03466112
- Testing
- endurance training, balance and tone program
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich